“Levothyroxine and other thyroid medications deplete your body of key nutrients it depends on to function well. Over time, they drain nutrients like B vitamins, magnesium, zinc, and selenium. These are the very nutrients your thyroid, adrenals, gut, and mitochondria rely on to recover and produce energy... you stay on it for the rest of…”

On the depletion mechanism. No study, guideline, or drug label was located stating that levothyroxine depletes B vitamins, magnesium, zinc or selenium. The most directly relevant document found is a clinician-facing drug-nutrient depletion reference, a document whose entire purpose is to catalogue medications that reduce nutrient status. In its table it lists levothyroxine and thyroid extract with the entry "No significant depletions confirmed," while listing specific depletions for other drug classes such as warfarin, lisinopril and others. This is a source with a commercial interest in identifying depletions, and it still records none for levothyroxine. The official NIH MedlinePlus levothyroxine monograph and the Cleveland Clinic patient information both discuss nutrient interactions in the opposite direction: supplements and minerals affect levothyroxine, not the reverse. Cleveland Clinic notes that biotin (vitamin B7) can interfere with thyroid function test results and advises stopping biotin supplements two days before bloodwork. Known interactions in this class involve calcium and iron reducing levothyroxine absorption, which is why separated dosing is advised. None of these documents describe levothyroxine causing depletion of B vitamins, magnesium, zinc or selenium. On nutrients and thyroid disease generally. There is a genuine literature here, but it says something different from the claim. A peer-reviewed review ("Minerals: An Untapped Remedy for Autoimmune Hypothyroidism?") examines how undetected deficiencies of zinc, selenium, iron and magnesium can adversely affect patients with Hashimoto's thyroiditis. That is an observation about deficiency prevalence and its consequences in thyroid patients, not a finding that medication caused the deficiency. A 2024/2025 double-blind randomized controlled trial tested selenium, zinc, magnesium and vitamins A, C and E at physiological doses for eight weeks in hypothyroid patients already on levothyroxine and vitamin D, which again positions micronutrients as a possible adjunct to levothyroxine rather than evidence of drug-induced depletion. On selenium specifically. A Cochrane systematic review found that selenomethionine 200 micrograms, alone or combined with levothyroxine, reduced anti-thyroid peroxidase antibody levels versus placebo in three studies, but the clinical relevance of those changes is unclear. The review concluded that the evidence to support or refute selenium supplementation in Hashimoto's is incomplete and not reliable enough to inform clinical decision making, with included studies at unclear to high risk of bias. On "lifelong medication, no healing." The American Thyroid Association task force concluded that levothyroxine should remain the standard of care for hypothyroidism, with no consistently strong evidence supporting the superiority of alternative therapies. Separately, a PLOS ONE cohort study notes that while primary hypothyroidism is generally considered a permanent condition requiring lifelong hormone therapy, it is reversible in some patients, and the study examined clinical factors predicting successful levothyroxine discontinuation. An active clinical trial registry entry (NCT07421869) similarly studies discontinuation in immune-checkpoint-inhibitor-induced hypothyroidism. So the premise that every hypothyroid patient is permanently medicated is not strictly correct, but the documented route off medication is physician-supervised dose reduction with thyroid function monitoring, not nutritional "root cause" therapy.